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ABSTRACT Responses of smooth muscle to kallikreins (EC
3.4.21.8) are generally considered to result from idnin formation.
This premise was reexamined with the isolated rat uterus. Rat
urinary kallikrein or bradykinin produced dose-dependent con-
tractions of rat uterus but kallikrein was 5-fold more potent than
bradykdnin. Kallikrein caused an immediate series of rythmic con-
tractions which could be increased gradually with subsequent ad-
dition of kininogen substrate. Kallikrein-induced contractions
were unaffected by carboxypeptidase B or a bradykinin antiserum
whereas bradykinin-induced contractions were attenuated or
abolished. Other serine proteinases, including trypsin, either did
not induce contraction in the absence of added kininogen or did
so minimally. Although small amounts of kininogen-like substrate
were found in uterine tissue, detectable kinin levels (>4 pg) could
not be found in bathing media during maximal kallikrein-induced
contractions or after uterine tissue was incubated with high con-
centrations of the enzyme in the presence of SQ 20881, a kdninase
II inhibitor. The data suggest that-uterine contraction produced
by a homologous kallikrein does not involve kinin formation but
results from an action of this serine proteinase upon other acces-
sible systems coupled to the contractile response.
Glandular kallikrein (EC 3.4.21.8) liberates lysylbradykinin
(kallidin) from kininogen substrates by limited proteolysis. Al-
though this serine proteinase can attack proinsulin or prorenin
in vitro (1, 2), responses of smooth muscle to this kallikrein are
attributed to kinin formation and a subsequent peptide-receptor
interaction (3-5). However, -Beraldo (6, 7) reported that rat
glandular kallikrein produced rat uterine contractions in the
absence of added kininogen or after pretreatment with actino-
mycin D or puromycin. It was suggested, but not shown, that
these agents might have inhibited endogenous kininogen syn-
thesis, and thus the effects of kallikrein were "direct." Con-
versely, the uterine contractile response to glandular kallikrein
was suggested to depend on a detected kininogen substrate in
the tissue (8, 9).
In the present study we have found that rat glandular kalli-
krein can cause contraction ofthe rat uterus without detectable
kinin liberation.
MATERIALS AND METHODS
Materials. Rat urinary kallikrein B was purified to homo-
geneity with ammonium sulfate fractionation and chromatog-
raphy on DEAE-cellulose, CM-cellulose, and Sephadex G-100.
"Vertical slab" polyacrylamide gel electrophoresis produced a
single band after Coomassie blue staining. The preparation was
also homogeneous when analyzed by polyacrylamide isoelectric
focusing (10). An antiserum to pure kallikrein B was raised in
a sheep (10). Human urinary kallikrein was purified to homo-
geneity with a modification of the scheme described for rat
urinary kallikrein and with aprotinin-agarose affinity chroma-
tography as described (11). Another rat urinary alkaline esterase
with kininogenase activity, called rat urinary esterase A (12, 13),
was separated from rat urinary kallikrein by DEAE-cellulose
column chromatography at pH 7.0 and further purified by
aprotinin-agarose affinity and Sephacryl S-200 column chro-
matography (12).
Trypsin (bovine pancreas, type III, twice crystallized) and
17,&estradiol were purchased from Sigma; carboxypeptidase B
was from Calbiochem-Behring. Bradykinin was obtained from
the Peptide Institute-Protein Research Foundation (Osaka, Ja-
pan) and its antiserum was prepared as described (14). Kinin-
ogen substrate was obtained from dog plasma treated for 1-3
hr at 600C as described (15).
Isolated Rat Uterus Preparation and Bioassay. Virgin female
Sprague-Dawley rats (100-150 g) were injected subcutaneously
with 17/3estradiol (0.2 mg/ml in 95% ethanol) at 200 pg/kg 24
hr prior to sacrifice by cervical dislocation. The uterine horns
were removed into ice-cold de Jalon's solution (containing the
following [g/liter]: NaCl, 9; KC1, 0.42; glucose, 0.5; NaHCO3,
0.5; and CaCl2, 0.03). The mesentery was removed and horns
were trimmed to 2 cm long. They were attached by a central
suture to a tissue hanger and placed in a double-walled bath
containing 10 ml ofde Jalon's solution and aerated with 95% 02/
5% CO2 at 270C. After a 1-hr equilibration period, tension was
readjusted to 1 g and isometric responses were recorded with
a Grass force displacement transducer (FTO3C) and polygraph.
Tissue Kininogen and Generated Kinin. Uterine kininogen
concentration was measured with a modification of the method
of Diniz and Carvalho (16). Rat uterine horns were removed,
freed offat, weighed, minced, and homogenized in 10 ml ofice-
cold Tyrode's solution with an all-glass conical homogenizer and
subsequently with a Polytron PT ST (Brinkmann) for 15 sec at
maximum setting. The homogenates (10 ml) were treated with
0.5% deoxycholate for 30 min at room temperature and then
centrifuged at 20,000 x g for 30 min. The supernatant was then
desalted through Sephadex G-25 via centrifugation (17). Protein
concentration was measured by the procedure of Lowry et aL
(18) with bovine serum albumin as the standard.
Uterine extracts were divided into three groups: untreated,
heat-treated (600C, 60 min), and boiled (100TC, 10 min). A sam-
ple (0.2 ml) of each extract was added to 0.2 ml of 0.1 M phos-
phate, pH 8.5/30 mM sodium EDTA/3 mM 1,10-phenanthro-
line plus 0.05 ml of trypsin (0.9 MM), rat urinary kallikrein (30
nM), human urinary kallikrein (5 nM), rat urinary esterase A
(30 nM), or H20; the final volume was made 0.5 ml. Reaction
mixtures without uterine homogenates or enzymes were used
as blanks. After incubation at 37C for 60 min, reactions were
stopped by boiling for 20 min. Kininogen was measured by ra-
dioimmunoassay ofgenerated kinins (14) with bradykinin as the
standard. In addition, any in situ kinin-generating activity of
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kallikreins was measured by kinin radioimmunoassay of bath
media during contractile responses or after uterine strips were
incubated with supramaximal enzyme concentrations in the
presence of kininase II inhibition (SQ 20881, 100 tg/ml).
RESULTS
The typical and prompt dose-dependent contractile responses
of the rat uterus to kallikrein or bradykinin are shown in Fig.
1 (Upper). The cumulative dose-response curves to kallikrein
and bradykinin at concentrations ranging from 9.0 x 10-11 to
1.4 X 10-8 M. Calculated molar concentrations of kallikrein
required to produce 1.0- and 1.5-g increases in contractile force
were one-fourth and one-sixth the concentrations ofbradykinin
required to produce equivalent responses.
Kallikrein typically produced rapid and rhythmic contrac-
tions followed by spontaneous and full relaxation (Fig. 2). Sub-
sequent addition ofkininogen resulted in more rapid contractile
responses of augmented force with incomplete relaxation. Ki-
ninogen alone never induced uterine contraction (data not
shown). Because the kallikrein preparation used for the studies
was free of Mg2e, the observed rhythmic contractions were in-
duced by kallikrein and not by contaminating magnesium.
Carboxypeptidase B [peptidyl-L-lysine (L-arginine) hydro-
lase, EC, 3.4.17.2], which degrades kinins, did not alter con-
tractile responses to kallikrein but abolished those to bradykinin
(Fig. 3). Bradykinin responses were restored after removal of
carboxypeptidase B.
A bradykinin antiserum (1:20 to 1:20,000 dilution) was in-
cubated with either bradykinin (0.2 tiM) or kallikrein (60 gM)
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FIG. 1. (Upper) Typical dose-response relationshipe for kallikrein
(Left) and bradykinin (Right) in the rat uterus. In these studies, uteri
were washed with fresh medium as soon as the contractile response
reached its peak. (Lower) Dose-response curves for kallikrein (A) and










FIG. 2. Effect of added kininogen on kallikrein-induced contrac-
tions in the uterus. Kallikrein (0.6 nM) causes repetitive contractions
followed by full relaxation. Addition of 0.1 ml of dogplasma kininogen
results in a further and time-dependent increase in contractility.
organ bath. There was a dose-dependent inhibition of contrac-
tile responses to bradykinin by antiserum, with a50% reduction
of response at a 1:2000 antiserum dilution (final bath dilution,
1:200,0000) (data not shown). Responses to kallikrein were
never affected by preincubation with bradykinin antiserum.
Preimmune serum had no effect on uterine contractions pro-
duced by either bradykinin or kallikrein. Kallikrein-induced
contractions were not affected by bradykinin antiserum added
to the organ bath, but bradykinin-induced contractions were
significantly reduced (Fig. 4). Bradykinin responses were re-
stored after removal of antiserum.
Responses to other serine proteinases known to liberate ki-
nins from kininogen substrates were studied. Human urinary
kallikrein (11), rat urinary esterase A (12), and trypsin produced
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FIG. 3. Effect of carboxypeptidase B on kallikrein- and bradyki-
nin-induced contraction in the rat uterus. (Upper) Typical tracings of
contractions produced by kallikrein (K) or bradykinin (BK) before,
during, and after addition of carboxypeptidase B (0.37 unit/ml, CBP).
As soon as the contractile response reached its peak, the bath fluid was
removed and the tissue was washed with fresh medium. (Lower) Con-
tractile responses as mean (±SEM) percentage of control before (i),
during (n), and after (o) addition of carboxypeptidase B (n = 7).
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FIG. 4. Effect of bradykinin antiserum on kallikrein- and brady-
kinin-induced contraction in the rat uterus. (Upper) Typical tracings
of contractions produced by kallikrein (K) or bradykinin (BK) before,
during, and after addition of bradykinin antiserum (BK-Ab) (1:2000,
final bath dilution). Uteri were washed with fresh medium as soon as
the contractile response reached its peak. (Lower) Contractile re-
sponses as percentage of control before (M), during (M), and after
(o) addition of the antiserum (n = 6).
bated with the enzyme, and these responses always were abol-
ished by carboxypeptidase B (0.37 unit/ml). However, these
proteases alone either did not cause uterine contraction or pro-
duced minimal responses (<10% ofthat seen with rat kallikrein)
in concentrations up to 50-fold greater than that of rat kallikrein
CTable 1).
The role ofendogenous kininogen in the contractile response
to kallikrein was assessed by measurement of uterine homog-
enate kininogen content and enzyme-induced kinin release.
Released kinins were measured by a direct radioimmunoassay
(14). Untreated, heat-treated (600C, 60 min), or boiled (10 min)
uterine homogenates were treated with typsin (0.9 tiM). Mean
(± SEM) kininogen content, in terms of the released kinin mea-
sured by radioimmunoassay, was 29.3 ± 1.9, 30.7 ± 0.3, and
26.5 ± 0.7 ng of kinin equivalents/mg protein in untreated,
heat-treated, or boiled homogenates, respectively (n = 4). Ex-
tracts treated with rat urinary kallikrein (30 nM), human urinary
kallikrein 50 nM), or rat urinary esterase A (30 nM) contained
Table 1. Effect of kininogenases on rat uterine contraction
Bath concentration, % of max
Enzyme M x 1010 contraction
Rat urinary kallilrein 6 100
Human urinary kallikrein 60 0
Rat urinary esterase A 60 0
Trypsin 30-300 <10
Measurements were repeated at least three times in each case. The
specific activities of rat urinary kallikrein, human urinary kallikrein,
andraturinary esteraseAwere 125, 74, and 550 Tos-Arg-OMe esterase
units/mg, respectively. One unit is defined as that amount of enzyme
which hydrolyzes 1.0 gmol of Tos-Arg-OMe permin atpH 8.0 and 30"C
in a standard titrimetric assay (17).
2.0, 1.5, or 1.2 ng of kinin equivalents/mg protein, respec-
tively. Similar results were observed with heated and boiled
uterine extracts. Thus, the rat kallikrein (and other kininogen-
ases) at supramaximal concentrations with respect to contractile
activity released <10% of the kinin released by trypsin.
Free kinin was not found in uterine extracts. The de Jalon's
solution surrounding isolated rat uteri (n = 3), producing 2.5
g ofcontractile force in response to kallikrein (4 nM), was with-
drawn and kinin content was measured by radioimmunoassay.
No detectable kinin levels (<4 pg per assay tube) were found
in 0. 1-ml aliquots of the media; recovery of added kinin was
98%. Finally, 2-cm uterine strips were incubated in de Jalon's
solution with rat urinary kallikrein (0.5-4 nM) in the absence
or presence of the kininase II inhibitor SQ 20881 (100 /ug/ml)
for periods of 10, 30, and 60 min. No detectable kinin was pres-
ent in the incubated media.
DISCUSSION
The present study shows that rat uterine contraction produced
by a rat glandular kallikrein occurs without detectable kinin
release. This conclusion is supported by the following findings.
First, the enzyme alone produced prompt contractions not
typical of those which result from a time-dependent initial rate
of enzymatic action and product formation. The enzyme is 4-
to 6-fold more potent than the product bradykinin, used for
comparison as bradykinin is 1.6-fold more potent that kallidin
in the isolated rat uterus (19).
Second, the addition of a kininogen substrate to the organ
bath after kallikrein has initiated maximal and rhythmic re-
sponses produced a time-dependent further increase in con-
tractility, as would be expected secondary to product formation.
Third, both carboxypeptidase B (a nonspecific kininase) and
a specific kinin antiserum abolished the uterine contractile re-
sponses to bradykinin but did not affect those to kallikrein.
Fourth, other potent kininogenases, including human uri-
nary kallikrein (11), rat urinary esterase A (12), and trypsin, in
amounts much larger than those of the rat enzyme either did
not induce uterine contraction or did so minimally
Fifth, there was no relationship between the calculated
amount of uterine kininogen detected after enzymatic treat-
ment and the ability of the enzymes to induce contractile re-
sponses. That is, amounts ofrat urinary kallikrein supramaximal
in terms of contractile responses released <10 % of the kinin
from uterine extracts that was released by trypsin; the latter
produced contractile responses <10% of those of kallikrein in
concentrations up to 50-fold higher.
Finally, kinin could not be detected with a sensitive radioim-
munoassay while uteri were contracting in response to kallikrein
or after prolonged incubation of uteri with excess amounts of
enzyme in the presence of kininase II inhibition.
It is known that other rat glandular kallikreins (e.g., pan-
creatic and salivary) cause the isolated rat uterus to contract (20,
21); these enzymes have been considered to be 500-fold more
potent than trypsin insofar as this effect is concerned (22). How-
ever, because small but detectable quantities of a kinin-releas-
ing substrate have been found within the organ (23), the mech-
anism of kallikrein-induced uterine contraction has been
uncertain. The possibility exists that this detectable kininogen
is residual from plasma which contains 3-10 Zg of bradykinin
equivalents/ml. On the other hand, the possibility exists that
rat glandular kallikrein uniquely releases kinin from some en-
dogenous uterine kininogen to a location not accessible to avail-
able kinin antibody or kininase and in quantities too small to be
detected by radioimmunoassay. This seems unlikely because
the efficiency of trypsin as a kdninogenase is not paralleled by
contractile efficacy.
6156 Biochemistry: Chao et aL
Proc. Natd Acad. Sci. USA 78 (1981) 6157
Fiedler (24) has pointed out that, although kallikreins are
defined by one function (i.e., the ability to liberate a kinin from
kininogen), definite proof that this is the only role of these en-
zymes is lacking. This is especially pertinent because activities
of these serine proteinases not related to kinin are now being
discovered. Thus, the abilities ofplasma or glandular kallikreins
to cleave proinsulin (1), activate prorenin (2), release renin (25),
attack angiotensinogen (26), and, now, contract the uterus sug-
gest that the enzymes have other important biologic functions.
It is now known that glandular kallikrein exists in rat plasma
(27). Aprotinin, an effective inhibitor ofglandular kallikrein, has
been found to decrease pregnant uterine muscular activity and
prolong the duration of parturition (28). Whether the enzyme
has some role in parturition-for example, via the adenyl cy-
clase activation that occurs in response to various serine pro-
teinases in the rat ovary (29)-remains to be determined.
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